Multiple system atrophy: an update and emerging directions of biomarkers and clinical trials
Authors:
Open Access
- 14 March 2024
- journal article
- review article
- Published by Springer Nature in Journal of Neurology
- Vol. 271 (5) , 2324-2344
Abstract
Multiple system atrophy is a rare, debilitating, adult-onset neurodegenerative disorder that manifests clinically as a diverse combination of parkinsonism, cerebellar ataxia, and autonomic dysfunction. It is pathologically characterized by oligodendroglial cytoplasmic inclusions containing abnormally aggregated α-synuclein. According to the updated Movement Disorder Society diagnostic criteria for multiple system atrophy, the diagnosis of clinically established multiple system atrophy requires the manifestation of autonomic dysfunction in combination with poorly levo-dopa responsive parkinsonism and/or cerebellar syndrome. Although symptomatic management of multiple system atrophy can substantially improve quality of life, therapeutic benefits are often limited, ephemeral, and they fail to modify the disease progression and eradicate underlying causes. Consequently, effective breakthrough treatments that target the causes of disease are needed. Numerous preclinical and clinical studies are currently focusing on a set of hallmarks of neurodegenerative diseases to slow or halt the progression of multiple system atrophy: pathological protein aggregation, synaptic dysfunction, aberrant proteostasis, neuronal inflammation, and neuronal cell death. Meanwhile, specific biomarkers and measurements with higher specificity and sensitivity are being developed for the diagnosis of multiple system atrophy, particularly for early detection of the disease. More intriguingly, a growing number of new disease-modifying candidates, which can be used to design multi-targeted, personalized treatment in patients, are being investigated, notwithstanding the failure of most previous attempts.Keywords
Funding Information
- Sichuan Science and Technology Program (2022ZDZX0023)
This publication has 233 references indexed in Scilit:
- Cognition in multiple system atrophy: a single‐center cohort studyAnnals of Clinical and Translational Neurology, 2020
- Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson DiseaseJAMA Neurology, 2018
- Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal FluidJAMA Neurology, 2017
- Natural history of pure autonomic failure: A United States prospective cohortAnnals of Neurology, 2017
- Variants associated with Gaucher disease in multiple system atrophyAnnals of Clinical and Translational Neurology, 2015
- Multiple System Atrophy and Amyotrophic Lateral Sclerosis in a Family With Hexanucleotide Repeat Expansions inC9orf72JAMA Neurology, 2014
- Are trials of intravascular infusions of autologous mesenchymal stem cells in patients with multiple system atrophy currently justified, and are they effective?Annals of Neurology, 2012
- A randomized trial of mesenchymal stem cells in multiple system atrophyAnnals of Neurology, 2012
- SNCA variants are associated with increased risk for multiple system atrophyAnnals of Neurology, 2009
- Multiplex Families With Multiple System AtrophyArchives of Neurology, 2007